News | Latest Breaking News Stories & Headlines

J&J to invest $2 billion to boost US manufacturing

Johnson & Johnson said today it would invest $2 billion in North Carolina as it aims to expand its US manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.

Business • 21 Aug

Johnson & Johnson beats profit estimates

Johnson & Johnson raised its full-year sales forecast today after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.

Business • 16 Jul

J&J's quarterly sales stood at $21.89 billion, up 2.4% from a year ago

J&J beats Wall Street quarterly sales & profit estimates

Johnson & Johnson today reported first-quarter revenue and profit above Wall Street estimates, driven again by strong sales of its cancer treatments including multiple myeloma medicine Darzalex.

Business • 15 Apr

J&J has been attempting to resolve US lawsuits through a subsidiary company's bankruptcy, after two previous bankruptcy attempts failed in other courts

US judge rejects J&J's $10 billion baby powder settlement

A US bankruptcy judge has rejected Johnson & Johnson's $10 billion proposal to end thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.

Business • 01 Apr

J&J has been on an acquisition spree to boost its drugs and device businesses

J&J beats quarterly sales and profit estimates

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter revenues and profit above Wall Street estimates today, driven by strong sales of its cancer treatments.

Business • 22 Jan

The increase would boost the size of the J&J settlement to more than $9 billion paid over 25 years

Johnson & Johnson adds $1.1 billion to proposed talc deal

Johnson & Johnson plans to pay an additional $1.1 billion to resolve tens of thousands of legal actions alleging its baby powder and other talc products caused cancer, two people familiar with the matter said.

Business • 05 Sep 24

Johnson & Johnson has beaten estimates for Q2 profit and revenues

J&J beats Wall Street estimates on strong drug sales

Johnson & Johnson has today beaten estimates for second-quarter profit and revenue, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.

Business • 17 Jul 24

Janssen to adopt Johnson & Johnson brand name in Ireland

Johnson & Johnson said today that its pharmaceutical business segment in Ireland will adopt the Johnson & Johnson brand name.

Business • 19 Jun 24

The acquisition gives J&J access to a device that uses shockwaves to break down calcified plaque in heart vessels

J&J agrees to buy Shockwave Medical for $12.5bn

Johnson & Johnson has agreed to buy Shockwave Medical for $12.5 billion, in a deal that would help broaden its portfolio of medical devices used in treating heart diseases.

Business • 05 Apr 24

J&J has maintained that its now-discontinued talc products are safe and do not cause cancer

J&J agrees to resolve 42 US states' talc investigations

Johnson & Johnson has toay reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh US competition from biosimilar versions next year.

Business • 23 Jan 24

Limerick based Johnson & Johnson has a workforce of 1,466

J&J Limerck eye care unit revenues rise to €1.24bn

Pre-tax profits at the Limerick-based Johnson & Johnson producer of eye-care products decreased by 15%to €458.97m in 2022.

Business • 04 Jan 24

The separation of Kenvue was the biggest shake-up in the healthcare conglomerate's history

J&J forecasts 12.5% growth in 2023 profit

Johnson & Johnson has today forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue.

Business • 30 Aug 23

J&J has placed huge bets on its newer cancer drugs, while also trying to bolster growth at its pandemic-hit medical devices business

J&J says cancer drugs, medical devices to drive growth

Johnson & Johnson has today forecast 2023 profit above Wall Street estimates, banking on demand for its cancer drugs such as Darzalex and the strength in its medical devices business.

Business • 20 Jul 23

The ruling is being viewed as a setback for the company as it seeks to settle thousands of similar cases

Johnson & Johnson to appeal €16.7m baby powder ruling

US pharmaceutical company Johnson & Johnson must pay $18.8m (€16.7m) to a California man who said he developed cancer from exposure to its baby powder, a jury has ruled.

US • 19 Jul 23

J&J has been facing thousands of lawsuits over talcum powder containing traces of asbestos blamed for causing ovarian cancer

J&J proposes $8.9bn settlement of talc cancer claims

US pharmaceutical giant Johnson & Johnson has proposed an $8.9 billion settlement to resolve years-old lawsuits claiming that its talcum powder products caused cancer.

Business • 05 Apr 23

The J&J site in Limerick is one of the largest contact lens manufacturing facilities in the world.

J&J to expand Limerick site, plans to create 80 jobs

The Johnson & Johnson Vision company, which manufactures eye health products at its plant in Limerick, has announced an expansion of its existing facility in Plassey.

Business • 16 Sep 22

Johnson & Johnson did not admit wrongdoing (File image)

J&J to pay $40.5m to settle New Hampshire opioid action

Johnson & Johnson has agreed to pay $40.5 million to settle New Hampshire's claims over the company's role in the opioid epidemic, averting a trial that had been scheduled to begin next week.

US • 01 Sep 22

The company's cornstarch-based baby powder is already sold in countries around the world

J&J to stop selling talc-based baby powder next year

Johnson & Johnson will stop selling talc-based baby powder globally in 2023, the drugmaker said.

World • 12 Aug 22

The company had earlier predicted as much as $3.5 billion in sales from the shot

J&J suspends sales forecast for Covid-19 vaccine

Johnson & Johnson has suspended its sales forecast for Covid-19 vaccines due to a global supply surplus and demand uncertainty - and cut its adjusted profit expectation, sending the drugmaker's shares down nearly 3%.

Business • 19 Apr 22

J&J said it would continue to supply medicines and medical devices to Russia

J&J suspends supply of personal care products to Russia

Johnson & Johnson has said today it would halt sale of personal care products in Russia, joining other companies that have limited their business in the country in response to its invasion of Ukraine.

Business • 29 Mar 22

Drugs manufactured in Ringaskiddy by Janssen include those for immunology and oncology patients

€150m Janssen investment to create up to 180 jobs

Up to 180 jobs are to be created by the pharmaceutical company Janssen Sciences Ireland in Co Cork.

Business • 25 Mar 22

Overall, J&J expects annual sales of $98.9 billion to $100.4 billion.

J&J expects 2022 Covid vaccine sales to jump up to 46%

Johnson & Johnson has said it expects to generate as much as $3.5 billion from the sale of its Covid-19 vaccine this year compared to $2.39 billion in 2021, in a sign of easing manufacturing problems and increasing demand.

Business • 25 Jan 22

J&J plans to split off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit

Johnson & Johnson plans to split into two companies

Johnson & Johnson said today that it is planning to break up into two companies, splitting off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit.

Business • 12 Nov 21

J&J has stuck to its Covid-19 vaccine sales target of $2.5 billion as it works through production challenges that have resulted in delays

J&J keeps vaccine sales outlook unchanged

Johnson & Johnson has today raised its annual adjusted profit forecast, but stuck to its Covid-19 vaccine sales target of $2.5 billion as it works through production challenges that have resulted in delays.

Business • 19 Oct 21

The J&J Covid vaccine is far behind on its schedule for deliveries in the US and Europe

J&J forecasts $2.5 billion in Covid vaccine sales

Johnson & Johnson has today forecast just $2.5 billion in 2021 sales of its Covid-19 vaccine, which has fallen way behind rival shots from Pfizer and Moderna as it deals with vaccine production issues and safety concerns.

Business • 21 Jul 21